XML 34 R22.htm IDEA: XBRL DOCUMENT v3.7.0.1
16. Stockholders' equity (deficit)
3 Months Ended
Mar. 31, 2017
Equity [Abstract]  
16. Stockholders' deficit

 

  16. Stockholders’ equity (deficit)

 

  a) Common shares

 

On February 2, 2017, the Company issued 1,200,000 common shares to a convertible note holder in terms of a returnable commitment fee. The shares are returnable to the Company if the convertible note is repaid prior to maturity, failing which the commitment fee will be earned. These shares are not accounted for as issued until such time as the probability of the commitment fee is assessed as probable or certain, refer note 12 above.

 

On February 14, 2017, in terms of the acquisition of 100% of the capital stock of Cranberry Cove Holdings Ltd. (“CCH”) from Leon Developments, the Company funded a portion of the acquisition by the issuance of 60,000,000 shares of the Company’s common stock at a market value of US$0.0364 per share, totaling $2,184,000, refer note 1 and 4 above.

 

  b) Warrants

 

In terms of the short-term Series L Convertible notes entered into with 3 parties, as disclosed in note 12 above, the Company awarded three year warrants exercisable over 2,366,666 shares of common stock, at an exercise price of $0.03 per share.

 

The fair value of Warrants awarded during the three months ended March 31, 2017 were valued at $92,620 using the Black Scholes pricing model utilizing the following weighted average assumptions:

 

   

Three months

ended

March 31, 2017

     
Calculated stock price   $ 0.04  
Risk free interest rate     1.48 %
Expected life of warrants (years)      3 years   
expected volatility of underlying stock     398 %
Expected dividend rate     0 %

 

The movement in warrants outstanding is summarized below:

 

          No. of shares   Exercise price per share   Weighted average exercise price
                   
Outstanding January 1, 2016                  6,300,000   $0.0033 to $0.03    $                 0.14
Granted                19,337,409                       0.03                   0.0300
Forfeited/cancelled                (6,000,000)                       0.15                   0.1500
Exercised                               -                              -                              -   
Outstanding January 1, 2017                19,637,409   $0.0033 to $0.03                   0.0030
Granted                  2,366,666                       0.03                   0.0300
Forfeited/cancelled                               -                              -                              -   
Exercised                               -                              -                              -   
Outstanding March 31, 2017                22,004,075   $0.0033 to $0.03   $0.0300

 

The following table summarizes information about warrants outstanding at March 31, 2017:

                   
  Warrants outstanding   Warrants exercisable
Exercise price No. of shares   Weighted average remaining years   Weighted average exercise price   No. of shares   Weighted average exercise price
                   
$0.0033             300,000    *                      300,000    
$0.03        21,704,075                     2.94                21,704,075    
                   
         22,004,075                     2.94    $               0.03            22,004,075    $                 0.03

* In terms of an agreement entered into with an investor relations company, 300,000 warrants were to be issued as part of the Investor Relations Agreement. These warrants have not been issued as yet, therefore the warrant terms are uncertain.

 

All of the warrants outstanding as of March 31, 2017 are vested. The warrants outstanding as of March 31, 2017 have an intrinsic value of $8,001.

 

  c) Stock options

 

Our board of directors adopted the GreeneStone Healthcare Corporation 2013 Stock Option Plan (the “Plan”) to promote our long-term growth and profitability by (i) providing our key directors, officers and employees with incentives to improve stockholder value and contribute to our growth and financial success and (ii) enable us to attract, retain and reward the best available persons for positions of substantial responsibility. A total of 10,000,000 shares of our common stock have been reserved for issuance upon exercise of options granted pursuant to the Plan. The Plan allows us to grant options to our employees, officers and directors and those of our subsidiaries; provided that only our employees and those of our subsidiaries may receive incentive stock options under the Plan. We have granted a total of 480,000 options as of March 31, 2017 under the Plan.

 

No options were issued, exercised or cancelled for the period under review.

 

The following table summarizes information about options outstanding as of March 31, 2017.

 

  Options outstanding   Options exercisable
Exercise price No. of shares   Weighted average remaining years   Weighted average exercise price   No. of shares   Weighted average exercise price
                   
$0.12             480,000                     2.59                   480,000    
                   
              480,000                     2.59    $               0.12               480,000    $                0.12

 

As of March 31, 2017, there was no unrecognized compensation costs related to these options and the intrinsic value of the options is $0.